Expand ROIV Menu
ROIV MENU

ROIV Latest Press Releases

-- August 6, 2026 --

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update Globe Newswire 7:00 AM
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 Globe Newswire 7:00 AM
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) Globe Newswire 7:00 AM

-- July 23, 2026 --

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM

-- May 20, 2026 --

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update Globe Newswire 7:00 AM

-- May 11, 2026 --

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM

-- April 2, 2026 --

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Globe Newswire 5:00 AM
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) Globe Newswire 5:00 AM

-- March 28, 2026 --

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis Globe Newswire 3:00 PM
Market Data Delayed 15 Minutes